Evidence map›Paper›PMID 39410009›Full record

ArticleCancers2024

Neoadjuvant Pembrolizumab Plus Chemotherapy in Early-Stage Triple-Negative Breast Cancer: A Nationwide Retrospective Turkish Oncology Group Study.

Ebru Karci, Ahmet Bilici, Buket Bayram, Melisa Celayir, Neslihan Ozyurt, Başak Oyan Uluc, Aynur Eken, Gul Basaran, Umut Demirci, Yasemin Kemal and 14 more

Abstract read
In one paragraph

Article in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Ebru KarciDepartment of Medical Oncology, Faculty of Medicine, İstanbul Medipol University, Istanbul 34214, Türkiye.
Ahmet BiliciDepartment of Medical Oncology, Faculty of Medicine, İstanbul Medipol University, Istanbul 34214, Türkiye.
Buket BayramDepartment of Medical Oncology, Koc University Hospital, Istanbul 34010, Türkiye.
Melisa CelayirDepartment of Medical Oncology, Faculty of Medicine, Mehmet Ali Aydınlar Acıbadem University, Istanbul 34752, Türkiye.
Neslihan OzyurtDepartment of Medical Oncology, Faculty of Medicine, Ordu University Training and Research Hospital, Ordu 52200, Türkiye.
Başak Oyan UlucDepartment of Medical Oncology, Faculty of Medicine, Mehmet Ali Aydınlar Acıbadem University, Istanbul 34752, Türkiye.
Aynur EkenDepartment of Medical Oncology, Ozel Ortadogu Hospital, Adana 67055, Türkiye.
Gul BasaranDepartment of Medical Oncology, Faculty of Medicine, Mehmet Ali Aydınlar Acıbadem University, Istanbul 34752, Türkiye.
Umut DemirciMedical Oncology Unit, Memorial Ankara Hospital, Ankara 06520, Türkiye.ORCID 0000-0002-4833-6721
Yasemin KemalDepartment of Medical Oncology, Faculty of Medicine, Altınbas University, Istanbul 34147, Türkiye.
Mehmet Berk OruncuDepartment of Medical Oncology, Faculty of Medicine, Ankara University, Ankara 06100, Türkiye.ORCID 0000-0002-2808-4897
Omer Fatih OlmezDepartment of Medical Oncology, Faculty of Medicine, İstanbul Medipol University, Istanbul 34214, Türkiye.
Fatih SelcukbiricikDepartment of Medical Oncology, Koc University Hospital, Istanbul 34010, Türkiye.
Taner KorkmazDepartment of Medical Oncology, Faculty of Medicine, Mehmet Ali Aydınlar Acıbadem University, Istanbul 34752, Türkiye.
Ismail ErturkMinistry of Health Gülhane Training and Research Hospital, Ankara 06010, Türkiye.
Irem BilgetekinMedical Oncology Unit, Memorial Ankara Hospital, Ankara 06520, Türkiye.
Serkan CelikDepartment of Medical Oncology, Yeditepe University, Istanbul 34755, Türkiye.
Alper TurkelDepartment of Medical Oncology, Abdurrahman Yurtaslan Ankara Oncology Research and Training Hospital, Ankara 06200, Türkiye.
Ali AlkanDepartment of Medical Oncology, School of Medicine, Mugla Sıtkı Kocman University, Mugla 48000, Türkiye.
Abdullah SakinDepartment of Medical Oncology, Faculty of Medicine, İstanbul Medipol University, Istanbul 34214, Türkiye.
Orcun CanDepartment of Medical Oncology, Faculty of Medicine, Mehmet Ali Aydınlar Acıbadem University, Istanbul 34752, Türkiye.
Meral GunaldiDepartment of Medical Oncology, Faculty of Medicine, Aydın University, Istanbul 34295, Türkiye.
Ece EsinDepartment of Medical Oncology, Bayındır Hospital, Ankara 06250, Türkiye.ORCID 0000-0002-7073-9906
Ozcan YildizDepartment of Medical Oncology, Faculty of Medicine, İstanbul Medipol University, Istanbul 34214, Türkiye.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

event-free survivalneoadjuvant therapyoverall survivalpathological complete responsepembrolizumabreal worldsafetytriple-negative breast cancer

Identifiers

PMID39410009
PMCPMC11475936

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.